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Abstract 1 
  2 
Breast cancer is known to be a heterogeneous disease driven by a large repertoire of 3 
molecular abnormalities, which contribute to its diverse clinical behavior. Despite the 4 
success of targeted therapy approaches for breast cancer patient management, there is still 5 
a lack of the molecular understanding of aggressive forms of the disease and clinical 6 
management of these patients remains difficult. The advent of high throughput sequencing 7 
technologies, have paved the way for a more complete understanding of the molecular 8 
make-up of the breast cancer genome. As such, it is becoming apparent that disruption of 9 
canonical splicing within breast cancer governs its clinical progression. In this review, we 10 
discuss the role of dysregulation of spliceosomal component genes and associated factors 11 
in the progression of breast cancer, their role in therapy resistance and the use of 12 
quantitative isoform expression as potential prognostic and predictive biomarkers with a 13 
particular focus on oestrogen receptor positive breast cancer. 14 
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Introduction 29 
Dysregulation of alternative splicing (AS) is widely considered a new hallmark of cancer and 30 
its products are being acknowledged as potentially useful biomarkers (Ladomery 2013). 31 
Canonical RNA splicing takes place in all mammalian cells and during this process pre-32 
mRNA becomes mature mRNA via the excision of introns and pasting together of exons 33 
(Figure 1). Alternative splicing affects about 90% of human genes resulting in a diverse 34 
selection of isoforms from one gene, each having different structural and functional 35 
properties that leads to a larger and more diverse cellular proteome. Indeed throughout 36 
evolution alternative splicing has been used to propel species development evidenced by an 37 
increase in AS in higher eukaryotes compared to lower (Keren, et al. 2010).  38 
 39 
Splicing is performed by the spliceosome which is a multi-protein complex called a 40 
“metalloribozyme” that is made up of 5 small nuclear riboproteins (snRNPs) that contain 41 
snRNAs and a large number of accessory proteins to recognize the pre-mRNA being 42 
spliced. Assembly of this complex takes place during transcription suggesting that 43 
transcription and splicing machineries are space restricted as they happen closely in time 44 
(Herzel, et al. 2017). The most commonly occurring spliceosome is the U2-dependent 45 
spliceosome that is assembled from the U1, U2, U5 and U4/U6 snRNPs and is responsible 46 
for the splicing of 99% of human introns as reviewed in Dvinge et al. (Dvinge, et al. 2016). 47 
Splicing is a two-step reaction involving transesterification occurring between two RNA 48 
nucleotides. The spliceosome recognizes introns containing the consecutive nucleotides GU 49 
at the 5’ splice site (SS) by U1 snRNP binding and an AG sequence at the 3 ’splice site by 50 
U2AF1 binding. In order to properly position the splicing machinery a key adenine (also 51 
referred to as the branch point (BP)) must be recognized by the Splicing Factor 1 protein 52 
(SF1)  as well as recognition of the polypyrimidine tract (poly-Y) by the U2 small nuclear 53 
RNA auxiliary factor 2 (U2AF2) (Pandya-Jones 2011). When the spliceosome complex is 54 
correctly bound to the mRNA it can carry out intron excision (Figure 1A). Exons are 55 
subsequently joined together and release a lariat intron, which is then degraded. The 56 
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spliceosome components are then released and recycled for use in subsequent rounds of 57 
splicing.  Splicing factors such as serine/arginine rich (SR) proteins (SRSF) and the splicing 58 
factor 3b complex (SF3B) work in association with the splicing core complex to coordinate 59 
canonical and alternative splicing. The expression levels and binding affinities of the different 60 
splicing factors plays a stoichiometric role in determining the final isoform of the protein that 61 
is to be expressed (da Luz, et al. 2017).  62 
 63 
Dysregulation of the normal splicing process governs many aspects of cancer cell biology 64 
such as managing cellular proliferation, angiogenesis, resisting apoptosis, adapting cell 65 
metabolism, enhancing the ability to invade and metastasize, and plays a role in resistance 66 
to cancer therapy (David and Manley 2010; Lee and Abdel-Wahab 2016). The role of 67 
alternative splicing in disease can result from aberrant splicing of a gene due to incorrect 5’ 68 
or 3’ splice site recognition leading to intron retention, exon skipping or exon inclusion 69 
(Figure 1A). AS may then lead to a premature stop codon resulting from a frame-shift, 70 
whereby these transcripts are subsequently degraded by nonsense mediated decay (NMD) 71 
(Figure 1B). There are multiple ways in which a cancer cell can induce aberrant splicing 72 
including: 1) when there is a mutation in the exon or surrounding introns that compromises 73 
the canonical splicing signal thereby allowing an alternative signal to dominate and an 74 
aberrant mRNA to be made; 2) a mutation in one of the splicing regulators interrupts splice 75 
site selection and results in a pattern of alternative splicing in multiple genes; 3) changes in 76 
histone acetylation of alternative exons (Khan, et al. 2014) and 4) alterations in other RNA-77 
binding proteins, splicing enhancers and suppressors, or lncRNAs.  Such splicing errors can 78 
lead to alterations in relative isoform expression of a particular mRNA or lead to an aberrant 79 
protein that has a change of function. A more detailed discussion on points 1 and 3 are 80 
detailed elsewhere (Martinez-Montiel, et al. 2017). Aberrantly spliced apoptotic genes such 81 
as the RNA binding protein RBM5 have been implicated in breast cancers as having an 82 
opposing role because the resulting isoform is more anti-apoptotic (Fushimi, et al. 2008). 83 
Another example is the B-cell lymphoma gene, Bcl-x, which can be spliced into two different 84 
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isoforms, long and short. Bcl-x(L) has anti-apoptotic properties where as Bcl-x(s) has pro-85 
apoptotic properties. High levels of Bcl-x(L) are seen in various types of cancer (Boise, et al. 86 
1993; Fushimi et al. 2008; Takehara, et al. 2001). A similar situation is seen with the myeloid 87 
cell leukemia-1 gene and its’ two isoforms Mcl-1(s) and Mcl-1(L). The long isoform is anti-88 
apoptotic and seen frequently increased compared to the short isoform in breast and ovarian 89 
cancer cells and is linked to gene amplification of MCL-1 itself (Bae, et al. 2000; Bingle, et al. 90 
2000; Gautrey and Tyson-Capper 2012). The choice between the long and short isoform is 91 
influenced by the splicing factors SRSF1 and SRSF5, which are also frequently upregulated 92 
in breast cancer (Gautrey and Tyson-Capper 2012). 93 
 94 
Managing key cellular processes such as epithelial to mesenchymal differentiation (EMT) is 95 
a clear advantage of being able to manipulate the expression of different isoforms of a 96 
certain gene (Shapiro, et al. 2011). As such, acquiring the ability to hijack these processes is 97 
critical in the evolution of a cancer cell in order to provide a fitness advantage. Given this, it 98 
is reasonable to postulate that the characterisation of the splicing program of a cancer cell 99 
could predict its genomic and mutational status and potentially treatment outcome (Danan-100 
Gotthold, et al. 2015). Indeed, differential expression of AS transcripts in specific subtypes of 101 
breast cancer may add additional prognostic information in addition to canonical gene 102 
expression or protein expression biomarkers.  103 
 104 
 105 
 106 
Evidence of splicing dysregulation in breast cancer 107 
Since the seminal studies from Perou and colleagues describing the intrinsic subtypes of 108 
breast cancer (Perou, et al. 2000), it is now widely accepted that the molecular make-up of 109 
breast cancer is heterogenous and governed by differences in transcriptional make up. 110 
Inevitably this also applies to the degree of isoform usage in cancer cells as well. For 111 
instance, well known driver oncogenes and tumour suppressor genes such as ERBB2 and 112 
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BRCA1 are known to be differentially spliced in different subtypes of breast cancer (as 113 
reviewed by Martinez-Montiel et al. (Martinez-Montiel, et al. 2017)). BRCA1 which is 114 
involved in homologous recombination DNA repair, is alternatively spliced in breast cancer 115 
to exclude exon 11 which contains the nuclear localization signal (Thakur, et al. 1997). The 116 
∆11q isoform produces a protein that is absent from the nucleus and is therefore unable to 117 
assist in DNA damage repair. Studies have shown that down regulation of the full length 118 
nuclear BRCA1 isoform and overexpression of the cytoplasmic ∆11q isoform is evident in 119 
subsets of breast cancer and is potentially mediated through the presence of a non-120 
functional TRA2β splicing factor (Raponi, et al. 2014; Wiener, et al. 2015). Another example 121 
is the ERBB2 tyrosine kinase signalling receptor, which is often found as alternatively 122 
spliced in breast cancer as the ∆16HER2 isoform. ∆16HER2 is constitutively active as a 123 
homodimer and promotes transformation in the mammary gland (Marchini, et al. 2011). 124 
BRCA1 and ERBB2 splicing, as well as splicing of Bcl-x and Mcl-1 as described above, are 125 
examples of common driver oncogenes and tumour suppressor genes that can be aberrantly 126 
spliced in breast cancer. Alternative splicing has also been show to regulate protein diversity 127 
of the oestrogen receptor itself. In particular, previous studies have shown the ERα∆5 splice 128 
variant has a positive effect on activation of transcription in the absence of oestrogen leading 129 
to constitutive transcriptional activation (Bollig and Miksicek 2000; Fuqua, et al. 1991). ESR1 130 
aberrant splicing events have also been identified in circulating tumour cells from metastatic 131 
breast cancer patients that have progressed on endocrine therapy, suggesting a role in 132 
mediating resistance (Beije, et al. 2018). Current data sets describing alternative splicing 133 
events in the context of spliceosomal gene mutations however, do not show changes in 134 
splicing of the oestrogen receptor itself (Darman, et al. 2015; Maguire, et al. 2015). 135 
Alternative spliced isoforms of genes known to be transcriptionally regulated by the 136 
oestrogen receptor such as CyclinD1 (cyclin D1b) and FGFR1 (FGFR1-beta) are also 137 
associated with poor prognosis in ER+ breast cancer (Wei, et al. 2011; Wendt, et al. 2014). 138 
 139 
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Alternative spliced transcripts as prognostic and predictive biomarkers in breast 140 
cancer 141 
The recent advent of RNA-sequencing technologies has revolutionised our view of the 142 
molecular make up of breast cancer. These advances now allow accurate global 143 
quantification of the transcriptional isoform make-up in individual tumours rather than relative 144 
quantification that is based on microarray probe design.  Indeed, a number of studies have 145 
shown that alternative isoform usage can be specific to different breast cancer molecular 146 
subtypes (Gracio, et al. 2017; Menon, et al. 2014; Sebestyen, et al. 2015; Stricker, et al. 147 
2017; Zhao, et al. 2016).  For instance, Sebestyen et al. identified a specific 7 gene isoform 148 
signature that accurately identified basal-like breast cancers, including a number of known 149 
driver genes such as CTNND1 (Sebestyen et al. 2015). Analysis of the splicing balance 150 
(relative ratios of isoforms produced) in breast tumours revealed changes in isoform usage 151 
in oncogenic and tumour suppressive pathways that was not apparent when looking solely 152 
at gene expression data (Gracio et al. 2017). Importantly, it was found that the balance of 153 
different transcript isoforms was associated with patient prognosis. A subset of genes 154 
including the proto-oncogene MYB were identified to correlate with basal-like breast cancer 155 
patient survival based on varying isoform levels but not on whole gene expression analyses 156 
(Gracio et al. 2017). Additionally, splicing but not gene expression levels of immune related 157 
genes CCR7 and FCRL3 were found to determine the immune control of the tumour. This 158 
has potential relevance given the role of lymphocytic infiltration in prognosis in breast 159 
cancer. Differential isoform usage can also stratify between different molecular subtypes of 160 
breast cancer. Indeed, global dysregulation of splicing specific to individual subtypes may 161 
drive the heterogeneous nature of breast cancer due to variation in the cellular proteome. 162 
Stricker et al (Stricker et al. 2017) looked at the global isoform differences between ER+ and 163 
triple-negative breast cancer (TNBC) and identified a signature of subtype specific 164 
alternatively spliced transcripts. Interestingly around 63% of the genes that were found to be 165 
differentially expressed, between subtypes were also alternatively spliced.  The particular 166 
type of splicing that occurred between the subtypes (exon skipping, intron retention, 167 
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alternative acceptor or donor) however was not significantly different indicating the unique 168 
splicing programs of each intrinsic subtype is not necessarily due to the activity of one 169 
general splicing mechanism but more likely due to target gene selection (Stricker et al. 170 
2017). Interestingly, this study also identified a significant difference in the total expression 171 
of some spliceosomal component genes themselves, such as YBX1 and MAGOH 172 
suggesting dysregulation of spliceosomal component proteins governs splicing 173 
dysregulation. 174 
 175 
Although clear differences in transcript isoforms have been identified in different molecular 176 
subtypes of breast cancer, to date no study has assessed the value of alternatively spliced 177 
transcripts as prognostic and predictive clinical biomarkers for patient stratification and of 178 
treatment response to both standard chemotherapy and targeted endocrine therapy. 179 
Assessment of differences in transcript isoform expression could add much needed 180 
biomarkers for patients that are most likely relapse on standard of care therapy. Ideally this 181 
would need to be tested in the context of randomised clinical trial cohorts, where good 182 
quality RNA-sequencing data at sufficient depth is acquired. 183 
 184 
Dysregulation of spliceosomal factors in Breast Cancer 185 
Molecular alterations affecting spliceosomal component genes themselves are also known 186 
to be involved in breast cancer tumorigenesis. There is evidence that mutations, copy 187 
number alterations and differential expression of spliceosomal component genes and their 188 
interacting proteins are associated with specific molecular and histological subtypes of 189 
breast cancer as well as being associated with aggressive disease and resistance to therapy 190 
in multiple tumour types (Ng, et al. 2012; Siegfried and Karni 2017; Sotillo, et al. 2015; Stark, 191 
et al. 2009). These alterations are thought to drive breast cancer progression through 192 
specific or novel isoform selectivity of key genes (Anczukow, et al. 2015; da Luz et al. 2017; 193 
Gokmen-Polar, et al. 2015; Maguire et al. 2015; Martinez-Montiel et al. 2017; Silipo, et al. 194 
2015; Vanharanta, et al. 2014).  195 
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 196 
Mutations in spliceosomal component genes 197 
Mutations affecting different components of the spliceosome have been identified in a range 198 
of solid and non-solid malignancies (Biankin, et al. 2012; Furney, et al. 2013; 199 
Papaemmanuil, et al. 2011; Quesada, et al. 2011; Yoshida and Ogawa 2014).  Mutations in 200 
the splicing factor SF3B1 are the most common across multiple tumour types, and at 201 
particular high frequencies in myelodysplastic syndrome (MDS), chronic myeloid leukaemia 202 
(CLL), uveal melanoma, (UV), pancreatic cancer and breast cancer. Mutations generally 203 
cluster at hotspot amino acid residues K700, R625, K666, and H662 (Cerami, et al. 2012; 204 
Gao, et al. 2013). However, each cancer type harbours a different variation of hotspot 205 
mutations. For example, K700E mutations are invariably found in breast cancer, pancreatic 206 
cancer and CLL, whereas uveal melanoma and endometrial cancers harbour the R625, 207 
R666 and R662 hotspots, suggesting some tissue specificity of the mutations. SF3B1 208 
hotspot mutations in CLL are associated with a poor prognosis however in uveal melanoma 209 
and MDS the prognosis is better with the presence of an SF3B1 mutation (Furney et al. 210 
2013; Quesada et al. 2011). Interestingly, additional spliceosomal component genes are 211 
also recurrently mutated at high frequencies particularly in myleodysplastic syndromes, 212 
including U2AF1, which has a distinct S34F/Y hotspot mutation and mutations in SRSF2 that 213 
are associated with a poor outcome in MDS (Thol, et al. 2012); and ZRSR2. Both SRSF2 214 
and ZRSR2 both harbour mutations spread throughout the gene, suggestive of a tumour 215 
suppressive function (Yoshida, et al. 2011). Mutations in these genes including SF3B1 occur 216 
in a mutually exclusive manner in MDS, suggesting that cells may tolerate only a partial 217 
deviation from normal splicing activity. Indeed, these genes are all involved in the 3′-splice 218 
site recognition during pre-mRNA processing, inducing abnormal RNA splicing and 219 
compromised haematopoiesis (Yoshida et al. 2011), implicating splicing dysregulation as a 220 
major driving force behind the development of MDS.  221 
 222 
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Our group has explored the mutational repertoire of spliceosomal component genes in 223 
breast cancer from a meta-analysis of whole genome and exome sequencing data (Maguire 224 
et al. 2015) (Figure 2). This analysis identified that around 5.6% of unselected breast 225 
cancers have mutations in spliceosome component genes at low frequencies. The most 226 
common spliceosomal gene mutation is SF3B1, which is associated with ER+ breast cancer 227 
and seen in around 3% of ER+ tumours (Pereira, et al. 2016), whereas mutations in SON 228 
and SAP130 appear to be associated with ER- disease (Maguire et al. 2015). Interestingly, 229 
we identified SF3B1 K700E mutations at higher frequencies in some rarer histological 230 
subtypes of breast cancer including 16% of papillary carcinomas and 8% of mucinous 231 
carcinomas of the breast, suggesting they may underpin their biology (Maguire et al. 2015). 232 
SF3B1 K700E mutations were also found to associate with losses of 16q11-q13 and gains of 233 
16q12-q13 indicating a distinct mechanism of breast cancer progression independent of the 234 
canonical early event of 1q gain and 16q loss (Maguire et al. 2015).  235 
 236 
The association of SF3B1 mutations and breast cancer clinical prognosis however is 237 
unclear, although mutations are being increasingly seen in metastatic disease (Lefebvre, et 238 
al. 2016; Pereira, et al. 2016). Further studies however are needed in order to truly assess 239 
the effect SF3B1 hotspot mutations on outcome. Of note, SF3B1 mutations have been 240 
observed in adenoid cystic carcinomas of the breast (an ER-negative special histological 241 
subtype) that has an excellent clinical outcome and at increased frequency in ER+ mucinous 242 
and papillary carcinomas of the breast, These data perhaps suggest that SF3B1 mutations 243 
maybe associated with a good prognosis (Maguire et al. 2015; Martelotto, et al. 2015). 244 
 245 
SF3B is a complex that is part of the U2 spliceosome and controls 3’ SS recognition. Its core 246 
is required for alignment of the branch site proteins, which allows for correct branch site 247 
selection during the splicing process (Cretu, et al. 2016). SF3B1 (SF3B155) is the largest 248 
component of the SF3B complex and contains the HEAT superhelix domain consisting of 20 249 
tandem repeats of two alpha helices joined by a short loop. Mutations in the HEAT domains, 250 
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which are responsible for interacting with pre-mRNA and other pre-mRNA binding proteins, 251 
result in a change in the tertiary structure that causes the selection of an alternative branch 252 
site (Alsafadi, et al. 2016; Darman et al. 2015; Kesarwani, et al. 2017). It is not known 253 
however, whether the SF3B1 mutant protein has a stronger affinity for the newly exposed 254 
branch point sequence or if it is coping with a disruption in binding to the canonical branch 255 
point sequence (Darman et al. 2015). Indeed, mutations in SF3B1 lead to alternative 256 
branchpoint usage and subsequent usage of a 3’ cryptic SS. This leads to aberrant 257 
transcript expression and subsequent nonsense mediated decay of around half the aberrant 258 
transcripts and hence leads to protein downregulation (Alsafadi et al. 2016; Darman et al. 259 
2015; Kesarwani et al. 2017).  260 
 261 
Although present as hotspot single amino acid changes, SF3B1 mutations are thought to 262 
lead to a change in function.  This is because knockdown or overexpression of the mutant 263 
protein does not recapitulate the aberrant splice pattern seen in mutant versus wildtype 264 
patients (Alsafadi et al. 2016). Additional evidence suggests that these mutations may 265 
actually be loss of canonical function. For instance, using the Degron-knock in approach to 266 
inactivate mutant or wild-type alleles specifically, Zhou et al. found that degradation of only 267 
the mutant SF3B1 allele in heterozygous SF3B1 mutant cells had no effect on growth 268 
whereas degradation of only the wildtype allele resulted in a decrease in viability of the cells 269 
(Zhou, et al. 2015). This suggests that SF3B1 is not likely to be haploinsufficient given the 270 
cells are solely relying on the wildtype copy of the gene to survive. This observation helps 271 
explain why SF3B1 mutations are uniformly heterozygous, as two copies of the mutant allele 272 
would likely be lethal.  273 
 274 
The most common SF3B1 mutation in breast cancer is the K700E variant akin to CLL but 275 
K666Q and K666E are also observed, albeit at much lower frequencies (Maguire et al. 276 
2015). Gene expression analysis in ER-positive disease shows that SF3B1 mutations affect 277 
regulators of the cell cycle, metabolism, and motility as well as protein degradation and 278 
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apoptosis, and splicing regulation itself (Maguire et al. 2015). Commonly differentially spliced 279 
mRNAs have been associated with SF3B1 mutations across tumour types including uveal 280 
melanoma, chronic lymphocytic leukaemia, pancreatic cancer, and breast cancer. Although 281 
a large number of transcripts have been identified to be aberrantly spliced and some are 282 
cancer specific (e.g. ABCB7 alternative splicing is only observed in MDS and gives rise to 283 
increased mitochondrial iron accumulation found in MDS patients with ring sideroblasts 284 
(Dolatshad, et al. 2016), the overlap is rather strikingly consistent between tumour types, 285 
suggesting that there is a distinct signature of genes that are alternatively spliced and 286 
furthermore can be used as markers of the mutation status (Biankin et al. 2012; Dolatshad et 287 
al. 2016; Furney et al. 2013; Maguire et al. 2015; Obeng, et al. 2016; Quesada et al. 2011; 288 
Wang, et al. 2016). However, it has not yet been identified which of the many differentially 289 
spliced genes is/are responsible for the tumorigenic phenotype and if these are different 290 
between different cancer types. In our study, we used siRNA to silence different genes that 291 
had been identified as alternatively spliced in our data set as well as across multiple cancer 292 
types. Silencing eight different genes (ABCC5, ANKHD1, DYNLL1, F8, RPL31, TMEM14C, 293 
UQCC, and CRNDE) did not show any changes in viability (Maguire et al. 2015). Given 294 
around half of all aberrantly expressed transcripts are subjected to NMD, they could be 295 
acting as tumour suppressors rather than in an oncogenic manner and will need to be 296 
explored in the future.  297 
 298 
Spliceosomal component genes as oncoproteins in breast cancer 299 
As well as mutations, alterations in components of the spliceosome, such as deletions or 300 
amplifications, are commonly seen across breast cancer (Figure 2, Table 1). In a similar vein 301 
to spliceosomal component mutations, they may lead to dysregulation of canonical splicing. 302 
SF3B3 (SF3B130) a component of the SF3B complex has been found to be significantly 303 
overexpressed in ER+ breast cancers and is associated with aggressive disease and 304 
resistance to tamoxifen therapy (Gokmen-Polar et al. 2015). SF3B3 is positioned closely to 305 
SF3B1 in the U2 complex and helps maintain the HEAT domain’s structural plasticity and 306 
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has the ability to alter pre-mRNA splicing hence affecting gene expression in the cell 307 
(Garcia-Blanco, et al. 2004). Over-expression of SF3B3 has thus been postulated to 308 
contribute to spicing aberrations in cancer cells.  In clear cell renal cell carcinoma, SF3B3 309 
overexpression was found to increase the expression of the pro-proliferative full length 310 
isoform of EZH2 and not the commonly expressed EZH2∆14 that is found in normal tissue 311 
(Chen, et al. 2017), thus promoting tumorigenicity in vivo. It could be that EZH2 AS plays a 312 
role in mediating the aggressive behaviour in endocrine resistant ER+ breast cancer as well, 313 
however this has yet to be elucidated. SF3B3 has also been found to be amplified and highly 314 
expressed at the transcript level in basal-like breast cancers (Srihari, et al. 2016). Overall the 315 
level is actually higher in ER- than ER+ disease, perhaps highlighting the higher proliferative 316 
rate of these tumours.  317 
 318 
The SRSF family of proteins are serine-arginine rich splicing factors that are commonly 319 
found to be mutated or dysregulated in cancer (Das and Krainer 2014). These proteins 320 
contain RNA recognition motif (RPM) domains that contact the mRNA and also interact with 321 
other splicing machinery (Das and Krainer 2014). SRSF1 also referred to as SF2/ASF is the 322 
most common protein of this family to play a role in breast cancer and overexpression is 323 
associated with a poor prognosis in ER+ breast cancers (Anczukow, et al. 2012). 324 
Overexpressing SRSF1 in 3D mammary organotypic assays is associated with larger acini 325 
structures indicating its oncogenic phenotype (Anczukow et al. 2012). This study also 326 
highlighted specific isoform dysregulation of the tumour suppressors BIM and BIN1, which 327 
resulted in loss of their pro-apoptotic functions (Anczukow et al. 2012; Karni, et al. 2007). 328 
SRSF1 upregulation is thought to play a role in EMT through alternative splicing modulation 329 
of its transcriptional target genes (Valacca, et al. 2010). Mechanistically this is linked back to 330 
the splicing regulator Sam68, which modulates levels of SRSF1 (Valacca et al. 2010). It was 331 
found that SRSF1 is more likely to facilitate exon inclusion when it binds closer to the 5’ site 332 
of the splice junction and promotes exon skipping or inclusion when it binds to the 3’ end 333 
(Anczukow et al. 2015). SRSF1 was found to alternatively splice CASC4 by including exon 334 
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9, resulting in a longer protein. When tested alone, overexpression of this isoform of CASC4 335 
phenocopied the tumorigenic abilities of SRSF1 overexpression by increasing proliferation 336 
and acinar size and decreasing apoptosis (Anczukow et al. 2015). These data highlight 337 
promising targets for therapeutic development in patients with SRSF1 overexpression.  338 
 339 
Other members of the SRSF family have also been implicated in breast cancer. For 340 
instance, SRSF2 gene amplification at 17q25 has been observed in 6% of breast cancers, 341 
although it is uncertain whether this plays an oncogenic role, given evidence that mutations 342 
are loss of function in this gene (Chung, et al. 2017). Finally, SRSF4 overexpression has 343 
been identified in a small subset of breast cancer and its expression has been found 344 
responsible for cisplatin induced alternative splicing that leads to apoptosis. Experiments 345 
where SRSF4 was silenced showed a decrease in apoptosis upon treatment with cisplatin 346 
and highlight the possibility of modulating splicing to regulate chemotherapy sensitivity 347 
(Gabriel, et al. 2015).  348 
 349 
Dysregulation of spliceosomal accessory proteins 350 
Along with the major components of the spliceosome that were described above, there are 351 
also other regulators of splicing that have been found to be mutated or dysregulated in 352 
breast cancer. LIN28A has been identified specifically in HER2–positive breast cancer as 353 
being a regulator of alternative splicing through interactions with hnRNPA1 (Xiong, et al. 354 
2017; Yang, et al. 2015). Loss of LIN28A in breast cancer results in isoform switching of the 355 
ENAH gene, which is overexpressed in some primary breast tumours (Xiong et al. 2017; 356 
Yang et al. 2015). It has also been identified as a feature of the malignant phenotype in a 357 
model of breast cancer progression and has been correlated with an unfavourable outcome 358 
in HER2-positive breast cancer (Du, et al. 2012).  Another example are the epithelial splicing 359 
regulatory proteins (ESRP1 and ESRP2) which are splicing factors that have been found to 360 
regulate the alternative splicing that governs the epithelial to mesenchymal transition and 361 
are amplified in breast cancers (Bebee, et al. 2015; Brown, et al. 2011; Warzecha, et al. 362 
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2009) and regulate EMT in breast tumours via activating AKT signalling (Brown et al. 2011). 363 
The RNA binding protein RBFOX2 is also involved in cellular transition, whose upregulation 364 
can perturb splicing events in breast cancer (Du et al. 2012; Lapuk, et al. 2010). During 365 
EMT, RBFOX2-regulated splicing shifts from epithelial-to mesenchymal-specific events, 366 
subsequently leading to a higher degree of tissue invasiveness (Braeutigam, et al. 2014). 367 
Another RNA binding protein, RBM47, has the ability to alter splicing by binding to introns 368 
and 3’ UTRs and loss of expression has been shown to prevent breast cancer progression 369 
and metastasis (Vanharanta et al. 2014). Taken together these lines of evidence point to a 370 
fundamental role triggered by splicing dysregulation in breast cancer cells that can cause 371 
detrimental effects and lead to the progression of disease.  372 
 373 
Evidence of oncogene induced dependency on the spliceosome 374 
Aside from alterations in spliceosomal component genes themselves, there is emerging 375 
evidence that oncogene activation imparts a functional dependency on SF3B1 and other 376 
components in breast cancer. A number of spliceosomal component proteins are known 377 
transcriptional targets of the oncoprotein MYC (including SF3B1 and SRSF1), and have 378 
been shown to both contribute to and co-operate with MYC in malignant transformation 379 
(Das, et al. 2012; Koh, et al. 2015). For instance, MYC addicted triple-negative breast 380 
cancers cells have been shown to impart a specific dependency on the spliceosome via 381 
BUD31 and SF3B1 (Hsu, et al. 2015) and impaired tumorigenesis was observed when 382 
SF3B1 was knocked down or pharmacologically inhibited in breast cancer cells hyper 383 
expressing MYC (Hsu et al. 2015). This could be explained due to the increased burden put 384 
on the spliceosome when the rate of transcription is increased due to MYC signalling. 385 
Recently, knockdown of SF3B1 was found to result in apoptosis in TNBC with MCL-1 386 
inactivation being a likely mechanistic explanation, given MCL-1 is and SF3B1 splicing target 387 
(Gao and Koide 2013; Sridhar P, et al. 2017). Interestingly, MYC and MCL-1 have been 388 
shown to cooperate in chemo-resistant TNBCs (Lee, et al. 2017). This could be further 389 
support for the intricate co-operation of MYC with the spliceosome and the resulting changes 390 
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in isoform dominance that allow the manipulation of cancer cells. In addition, SRSF1 is a 391 
known direct target of MYC. MYC induction leads to SRSF1-mediated alternative splicing of 392 
key protein isoforms involved in proliferation and anchorage-independent growth such as 393 
MKNK2 and TEAD1 (Anczukow et al. 2012; Das et al. 2012), which is in part through 394 
potentiating eIF4E activation (Anczukow et al. 2012; Das et al. 2012). Together these 395 
studies suggest that multiple spliceosomal proteins are critical MYC targets that contribute to 396 
its oncogenic potential by enabling MYC to regulate the expression of specific protein 397 
isoforms via alternative splicing. 398 
 399 
Therapeutic targeting of the spliceosome 400 
There is emerging evidence that disruption of spliceosomal proteins induces selectivity to 401 
inhibitors that target the spliceosome. Indeed a number of these inhibitors have been 402 
developed including Spliceostatin A, Pladienolides (including E7107), and meyamycin 403 
analogues that are all specific SF3B inhibitors as reviewed in (Lee and Abdel-Wahab 2016) 404 
that inhibit canonical splicing (Kaida, et al. 2007). We, and others, have shown that SF3B1 405 
mutant cells selectively sensitive to spliceosomal inhibitors (Maguire et al. 2015; Obeng et 406 
al. 2016). Moreover, SF3b inhibition in SF3B1 mutant cells resulted in a change in the 407 
reversal of the conserved splicing signature, suggesting that SF3B1 mutations are change of 408 
function rather than loss of function and that these alterations in aberrant isoforms could be 409 
used as biomarkers of therapeutic response (Maguire et al. 2015).  There is additional 410 
evidence that other spliceosomal gene mutations can be therapeutically targeted with 411 
spliceosomal inhibitors. These include SRSF2 mutations, whereby genetically modified mice 412 
expressing the Srsf2(P95H) mutation were sensitive to treatment with the spliceosome 413 
inhibitor E7107, which decreased leukemic burden (Lee, et al. 2016).  Similar selective 414 
sensitivity in mutant U2AF1 cells to sudemycins has also been reported in in vitro and in vivo 415 
(Shirai C, et al. 2015). In addition, MYC addicted TNBC’s have been shown to be more 416 
sensitive to inhibition with the spliceosome inhibitor SD6 than MYC non-addicted cells are 417 
(Hsu et al. 2015), a mechanism that is likely due to the increased stress and dependency on 418 
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SF3B1 (as discussed above). Further functional studies in the context of clear cell renal 419 
carcinoma show that knockdown of SF3B3 in SF3B3 overexpressing cells in vivo reduced 420 
tumour growth, highlighting the potential utility of SF3b inhibitors as a therapeutic agent for 421 
patients with SF3B3 amplification and/or overexpression (Chen et al. 2017). These lines of 422 
evidence raise the possible clinical utility of SF3b inhibitors in patients with additional 423 
spliceosomal gene mutations as well as other indirect reliance on the spliceosome. Further 424 
studies are warranted to ascertain if overexpression of spliceosomal genes also confers 425 
sensitivity to these compounds in breast cancer.   426 
 427 
Phase one clinical trials have been performed for E7107 in patients with solid tumours and 428 
although the drug has been shown to be on target in patients (i.e. perturbs splicing), the US 429 
and European trials were suspended due to an unexpected toxicity involving bilateral optic 430 
neuritis (Eskens, et al. 2013; Hong, et al. 2014). Further studies to understand causes of 431 
toxicity as well as new clinical trials will be necessary to take advantage of splicing’s 432 
therapeutic vulnerability in cancer. Currently, H3 biomedicine is testing the compound H3B-433 
8800 which inhibits the SF3b complex and was successful in preclinical studies treating a 434 
range of spliceosomal mutant cancers (Buonamici, et al. 2016). The compound is now in 435 
phase one studies (NCT02841540) for Myelodysplastic Sydromes, Acute Myeloid Leukemia, 436 
and Chronic Myelomonocytic Leukemia.   437 
 438 
Conclusions 439 
Mutations and changes in expression of splicing factors that lead to aberrant splicing is a 440 
hallmark of cancer that is also relevant to breast cancer. Development of prognostic and 441 
predictive aberrant splicing signatures specifically to predict patients that will respond to 442 
endocrine (or indeed CDK4/6 inhibitor) therapy and could be used particularly useful going 443 
forward. The increasing technical advances in sequencing methodologies, particularly those 444 
that aim to increase RNA read lengths, will undoubtedly enhance the ability to detect these 445 
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events in the future and further increase our understanding of aberrant transcript expression 446 
on breast cancer tumorigenesis and therapy resistance.  There is increasing evidence that 447 
spliceosomal component genes themselves are dysregulated in breast cancer, through 448 
mutations in SF3B1 that are also observed in metastatic disease and upregulation of SF3B3 449 
and SRSF1 in particular, which are associated with resistance to endocrine therapy. 450 
Dissecting the function of the expression of the consequent alternatively spliced transcripts 451 
would give insight into the mechanism of these alterations and the role they play in therapy 452 
resistance. Indeed with the development of spliceosome inhibitors themselves, and exciting 453 
preclinical data in other tumour types highlights a potential novel treatment strategy in 454 
combination with endocrine therapy and CDK4/6 inhibitors for patients with metastatic 455 
disease with spliceosomal gene alterations. 456 
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Figures 
Figure 1: Mechanisms of alternative splicing in cancer 
 (A) Schematic of the possible ways in which alternative splicing can change the mRNA 
product. The product of canonical splicing is shown as well as the products of alternative 
splicing. Yellow represents non-canonical areas of the mRNA that are present in 
alternatively spliced transcripts. The black lines above the mRNA show where canonical 
splice sites are selected and the purple lines below the mRNA show where alternative splice 
sites are selected. Examples of genes for each event were obtained from (Darman et al. 
2015). (B) the most likely product of the mRNA is indicated with solid dark arrows and the 
less likely but still possible products are indicated with dashed black arrows.  
 
Figure 2: Summary of spliceosomal gene alterations in breast cancer 
(A) cBioportal analysis of alterations in spliceosomal component genes from all available 
breast cancer data sets (Cerami et al. 2012; Gao et al. 2013). (B) Breakdown of patients with 
alterations by subtype from METABRIC and TCGA data with available PAM50 subtype calls. 
Basal= 19.3%, Her2= 18.5%, Luminal A= 24.9%, Luminal B= 31.9%, Normal-like= 5.5%.  
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 Table 1 
 
Summary of spliceosome component genes and RNA binding proteins found altered in 
breast cancer.  
 
Splicing 
Factor/ RNA 
Binding Protein 
Gene Name Alteration Occurrence in 
BrCa 
Functional 
Impact 
SF3B1 Splicing factor 3B 
subunit 1 
Mutation 
and CNA 
3% Change of 
function, 
oncogenic 
SF3B3 Splicing factor 3B 
subunit 3 
CNA 1.7% Oncogenic 
SRSF1 Serine/arginine rich 
splicing factor 1 
CNA 8% Oncogenic 
SRSF2 Serine/arginine rich 
splicing factor 2 
CNA 6% Oncogenic 
SRSF3 Serine/arginine rich 
splicing factor 3 
CNA 1.1% Oncogenic 
SRSF4 Serine/arginine rich 
splicing factor 4 
CNA 0.6% Oncogenic 
RBFOX2 RNA binding protein 
fox-1 homolog 2 
CNA 0.7% EMT Regulator 
ESRP1 Epithelial splicing 
regulatory protein 1 
CNA 18% EMT Regulator 
RBM47 RNA binding motif 
protein 47 
CNA 1.4% Downregulation 
LIN28A Lin-28 Homolog A CNA 0.4% Loss of function 
 
Sourced from all breast cancer studies available in cBioportal.  CNA= Copy number 
alteration. n=4587 sequenced cases. 
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Table 2: Number and percentage of patients pertaining to each subtype with an alteration 
in the specified spliceosome component genes.  
 
 SF3B1 SF3B3 SRSF1 SRSF2 SRSF3 SRSF4 RBFOX2 ESRP1 RBM47 LIN28A 
Basal 
n= 391 
12 
(3.07) 
10 
(2.56) 
11 
(2.81) 
22 
(5.63) 
15 
(3.84) 
6  
(1.53) 
5  
 (1.28) 
84 
(21.48) 
13 
(3.32) 
1  
(0.26) 
Her2 
n= 287 
9 
(3.14) 
3 
(1.05) 
39 
(13.59) 
25 
(8.71) 
2 
(0.70) 
1  
(0.35) 
2   
(0.70) 
99 
(34.49) 
6 (2.09) 1  
(0.35) 
Luminal 
A 
n= 909 
40 
(4.40) 
17 
(1.87) 
31 
(3.41) 
26 
(2.86) 
5 
(0.55) 
2  
(0.22) 
2   
(0.22) 
103 
(11.33) 
5 (0.55) 3  
(0.33) 
Luminal 
B 
n= 590 
19 
(3.22) 
5 
(0.85) 
99 
(16.78) 
50 
(8.47) 
3 
(0.51) 
2  
(0.34) 
4   
(0.68) 
159 
(26.95) 
2 (0.34) 1  
(0.17) 
Normal 
Like 
n= 179 
4 
(2.23) 
3 
(1.68) 
10 
(5.59) 
7 
(3.91) 
0 
(0.00) 
1  
(0.56) 
0   
(0.00) 
23 
(12.85) 
1  
(0.56) 
0  
(0.00) 
 
Data was derived from METABRIC and TCGA samples with available PAM50 subtype scores 
(n=2363). Percentages in brackets. 
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